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ABSTRACT
Introduction. The chronic use of immunosuppressive drugs in renal transplant recipients
increases the risk of developing de novo malignancies. Herein we analyze the incidence of
de novo tumors and the potential role of sirolimus to improve cancer-specific survival
among a cohort at a single center.
Methods. This retrospective analysis of our 1,816 patients allografted between January
1983 and December 2009 sought subjects who developed de novo tumors. Epidemiological
and clinical data were examined using Mann-Whitney and Pearson’s chi-square or Fisher
exact tests for statistical comparisons of continuous and categorical variables, respectively.
Kaplan-Meier survival curves were used to determine cancer-specific survival according to
type of neoplasia and immunosuppressive regimen, namely, conversion to sirolimus.
Results. One hundred patients (5.5%) were diagnosed with a de novo malignancy. The
110 different cancers were diagnosed at a median interval of 73 months after kidney
transplantation. The overall cancer-specific survivals at 1 and 5 years after cancer diagnosis
were 87.0% and 76.9%, respectively. The 15 patients converted to sirolimus showed no
difference in survival.
Conclusion. The observed frequencies of cancer in our center are consistent with the
literature. Among our cohort, sirolimus did not significantly impact survival among
subjects who had de novo malignancies.
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iTHE QUALITY of life and survival rates for end-stagerenal disease patients who are on dialysis are im-
proved after successful kidney transplantation. However, de
novo malignancies after kidney transplantation have be-
come a major concern in recent years.1 Cancer-specific
ortality among renal transplant recipients is not negligi-
le. In fact, in the next 20 years, cancer is expected to be one
f the most important causes of death among this group of
atients.2 Several factors have been associated with the
increased incidence of de novo malignancies among trans-
plant recipients, namely sun exposure,3 extent and duration
f immunosuppression,4,5 concomitant viral infection,6 and
onger pretransplantation dialysis periods.7 Among the risk
factors associated with de novo malignancies in this setting,
the advanced age of the transplanted population and the
long-term immunosuppressive therapy are important con-
tributors to an increased number of malignancies.8
The management of the immunosuppressive regimen in
recipients who have de novo cancer after transplantation is
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Transplantation Proceedings, 43, 137–141 (2011)omplex and difficult. Dose reduction or withdrawal of
mmunosuppression seeks to recover the recipient’s defec-
ive immune system; however, it may be detrimental to graft
unction and survival. Ideally, the immunosuppressive reg-
men should not be a risk factor for cancer development. To
ddress this concern, sirolimus, a macrocyclic lactone, has
hown interesting properties. After many trials in animal
odels,9 conversion from cyclosporine to sirolimus in hu-
an renal transplant recipients who have cancer has resulted
n complete regression of posttransplant Kaposi’s sarcoma10
and lymphoproliferative diseases11 while maintaining graft
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138 BRANCO, CAVADAS, OSÓRIO ET ALfunction. Therefore, switching from cyclosporine to sirolimus
may have a potential role to treat malignancy in transplanted
patients without increasing the risk of graft rejection.
These malignancies can have three sources: transfer from
the donor, recurrence of a pre-existent malignancy, and de
novo.12–14 However, in this setting, the majority are de novo
malignancies.12–14 Some cancers are markedly increased in
solid organ transplant recipients: in particular, skin cancer,
non-Hodgkin’s and Hodgkin’s lymphoma, Kaposi’s sar-
coma, anogenital cancer, renal cell carcinoma, hepatocellular
carcinoma, and some sarcomas.15–21 In contrast, the incidence
f the most common solid tumors in the general population—
ung, prostate, colorectal, breast—is onlymodestly increased.15–21
Thus, it is essential not only to carefully screen the patient and
donor before transplantation, but also to prevent posttrans-
plant malignancies with general preventive measures. There-
fore, excessive immunosuppression should be avoided and the
best immunosuppressive regimen chosen.22,23 This article re-
orts the incidence of de novo malignancies among renal
ransplant recipients in a single transplantation center and
ssesses the impact on survival of changing the immunosup-
ressive regimen by the introduction of sirolimus.
METHODS
This retrospective analysis of all 1,816 patients undergoing renal
transplantation between January 1983 and December 2009 was
performed using our prospective database and approved by the
Institutional Review Board. We analyzed subjects developing de
novo cancers under immunosuppression. We excluded patients
Table 1. Epidemiological, Clinical Characteristics and Canc
Malignancy Accordin
Characteristic Cutaneous Hematological Gyneco
Male/female 31/11 9/2 0
Age at renal
transplantation (y)
45.5 (38–54.75) 37 (33.5–44) 39 (3
Duration of dialysis until
transplantation (mo)
44 (27–72) 30 (16–36) 45 (3
Time interval of tumor
development after
transplantation (mo)
73.5 (28–131.75) 125 (72–155.5) 42 (1
Cancer-specific survival
at 1-/5-years after
cancer diagnosis (%)
97.8/95.5 81.8/54.5 94.1
Table 2. Epidemiological, Clinical Characteristics and Canc
Malignancy According to Immunosuppre
Characteristics
Male/female
Age at renal transplantation (y)
Duration of dialysis until transplantation (mo)
Time interval of tumor development after transplantation (mo)
Cancer-specific survival at 1-/5-years after cancer diagnosis (%)
*Fisher’s exact test.
†Mann-Whitney test.
‡Chi-square test.with a pretransplantation diagnosis of cancer and those for whom
donor-transmitted cancer was suspected.
The collected data included: patient age at transplantation,
gender, duration of pretransplantation dialysis, donor type, immu-
nosuppressive regimen, time to de novo tumor development, tumor
type, treatment, and follow-up.
After diagnosing a de novo tumor, the usual procedure until 2003, was
reduction in immunosuppression; thereafter, newly diagnosed patients
were converted from a calcineurin inhibitor to a sirolimus regimen.
Follow-up visits were performedmonthly. Screening for malignancy
included annual abdominal ultrasound (including native kidneys and
renal graft) as well as a dermatologic examination, in addition to
procedures universally recommended for the general population.
The follow-up was defined as the time that had elapsed from
transplantation to cancer-related death, death unrelated to cancer,
or last visit with no evidence of de novo malignancy with a
functioning allograft.
Continuous variables are reported as median values and inter-
quartile range (IQR); categorical variables, as the number of
occurrences (n) and their frequency (%). Mann-Whitney and
Pearson’s chi-square or Fisher exact tests were used for statistical
comparisons of continuous and categorical variables, respectively.
Kaplan-Meier survival curves were plotted to determine cancer-
specific survival according to type of cancer and immunosuppres-
sive regimen (conversion or not to sirolimus). All tests were
two-sided with a significance level set at 0.05. Statistical analysis
was performed using MedCalc v.11.1.1.0 (MedCalc Software bvba,
Mariakerke, Belgium).
RESULTS
Among the 1,816 renal transplant recipients, 100 (5.5%)
subjects were diagnosed with 110 different de novo neo-
pecific Survival of Renal Transplant Patients With de Novo
Type of Neoplasm
l Gastrointestinal Urological Miscellaneous Overall
10/5 11/2 3/4 61/39
51 (46–55.5) 47 (41–56) 49 (35–53) 44 (36.75–54)
40 (25.5–55.5) 30 (16.5–54) 36 (9.5–80) 41 (19–68)
103 (50–125.5) 105 (40–137) 43 (23.5–60.5) 73 (28–127)
42.9/42.9 84.6/67.7 100/53.3 87.0/76.9
pecific Survival of Renal Transplant Patients With de Novo
Regimen (With or Without Conversion)
onversion to Sirolimus No Conversion to Sirolimus P Value
8/7 53/32 .57*
41 (34.5–49.5) 46 (37–55) .26†
30 (16–57) 41.5 (23.5–73.5) .29†
114 (50–125.5) 66.5 (25–128) .24†
79.4/79.4 88.2/76.9 .84‡er-S
g to
logica
/17
0–52)
1–66)
1–76)
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SIROLIMUS IMMUNOSUPPRESSION AND MORTALITY 139plasms which were identified at a median time from trans-
plantation of 73 months (IQR 28–127). Only two patients
received a living donor organ. Table 1 shows the general
features of the renal transplant recipients with de novo
malignancy according to type of neoplasm. Sixty-one pa-
tients were male; the overall median age at renal transplan-
tation was 44 years (IQR 36.75–54), the median duration of
Fig 2. Cancer-specific survival
curves according to tumor type.ialysis until transplantation was 41 months (IQR 19–68),
nd the overall cancer-specific survival at 1 and 5 years after
ancer diagnosis was 87.0% and 76.9%, respectively. Forty-
wo patients received antithymocyte globulin induction
herapy. Maintenance immunosuppression consisted of cy-
losporine prednisolone (n 57), cyclosporine azathioprine
prednisolone (n  24), cyclosporine  mycophenolate
Fig 1. Cancer-specific survival
curves according to immunosup-
pression regimen.
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140 BRANCO, CAVADAS, OSÓRIO ET ALmofetil  prednisolone (n  12), tacrolimus  mycophe-
nolate mofetil  prednisolone (n  6) and isolated tacroli-
us (n  1).
Fifteen patients who had de novo malignancies were
onverted to sirolimus. No statistically relevant differences
ere observed concerning clinical characteristics or tumor-
pecific survival between patients converted or not to
irolimus (Table 2). Table 3 depicts the distribution of
ancer types and mortality according to immunosuppres-
ion regimen. The cancer-specific survival curves according
o immunosuppressive regimen and tumor type are shown
n Figures 1 and 2.
DISCUSSION
In our cohort, the global incidence of 5.5% (100 patients
who developed 110 de novo malignancies) is consistent with
the literature.18 The relative frequency of de novo malig-
nancies was also similar to previous studies, with a signifi-
cant predominance of cutaneous (melanoma and non-
melanoma) neoplasms; whereas other malignancies, such as
colorectal, prostate, and stomach cancer, showed only slight
increases.18,24–26
Regarding cancer-specific survival, no significant differ-
ences were noted between sirolimus conversion or no-
Table 3. Distribution of Cancer Types and Number of Deat
Conversion
Type of Cancer N %
Con
Total
Skin BCC 18 16.4 —
Skin SCC 18 16.4 1
Melanoma 1 0.9 —
Kaposi sarcoma 6 5.5 2
Other skin cancer 3 2.7 —
NHL 9 8.2 2
Hodgkin lymphoma 2 1.8 —
Breast 7 6.4 1
Ovary 2 1.8 —
Cervix 3 2.7 1
Vulva 6 5.5 —
Stomach 6 5.5 2
Duodenum 1 0.9 —
Colon 5 4.5 2
Liver 3 2.7 —
Kidney 6 5.5 2
Urothelium 3 2.7 1
Prostate 4 3.6 —
Lung 1 0.9 —
Soft tissue sarcoma 1 0.9 —
Mouth 1 0.9 —
Parotid gland 1 0.9 —
Thyroid 3 2.7 1
110 100 15BCC, basal cell carcinoma; SCC, squamous cell carcinoma; NHL, Non-Hodgkins
*Fisher’s exact test.irolimus regimens. Because sirolimus was only recently
ntroduced in our clinical practice, our cohort exhibits a
horter follow-up for the this regimen. Also, the number of
atients who have de novo malignancies under immunosup-
ressive regimens with sirolimus was smaller (although
very recent patient with de novo malignancy has been
onverted to a sirolimus immunosuppressive regimen)
hich limits the comparisons and may justify the lack of a
ignificant difference in survival. Comparing the two groups
ccording to immunosuppressive regimen, potentially more
ggressive tumors in the sirolimus group could account for
he lack of survival benefit. Gastrointestinal tumors have a
ismal prognosis, whereas cutaneous neoplasms show the
est survival. Finally, the pattern of initial immunosuppres-
ion and its heterogeneity in patients who develop de novo
ancers may have important roles influencing the survival of
hese patients.
Sirolimus displays a different immunosuppressive mech-
nism from cyclosporine. It complexes with FK binding
rotein complex 12, thereafter binding with high affinity to
he mammalian target of rapamycin. Conversion from
yclosporine to sirolimus in renal allograft patients who
ave de novo Kaposi’s sarcoma10 or de novo lymphoprolif-
erative disease11 was associated with regression of the
cording to Immunosuppression Regimen (With or Without
irolimus)
n to Sirolimus No Conversion to Sirolimus
P Value*Deceased Total Deceased
— 18 — 1
— 17 1
— 1 1
— 4 —
— 3 —
— 7 4 0.45
— 2 1
— 6 2 1
— 2 1
— 2 —
— 6 —
1 4 2 1
— 1 —
1 3 1
— 3 3
— 4 — 1
1 2 1
— 4 1
— 1 1 1
— 1 1
— 1 —
— 1 —
— 2 —
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SIROLIMUS IMMUNOSUPPRESSION AND MORTALITY 141malignancy with a survival benefit. In a single-center study
of 1,008 renal transplants followed up for 5 years, a
combination regimen of sirolimus plus corticosteroid re-
sulted in a reduction in the incidence of non-melanoma skin
cancers as well as of native renal cell carcinoma.27 However,
sirolimus has its own set of side effects, such as dyslipide-
mia, bone narrow suppression, reduced or delayed wound
healing, decreased insulin sensivity, and impaired male
fertility28; additionally, grafts can leak more proteins when
reated with sirolimus.29 Furthermore, the use of a de novo
irolimus-based, calcineurin inhibitor-free regimen has a
istinct learning curve, requiring appreciation of these side
ffects, patient education, and careful monitoring of blood
evels. In a large, primarily European, multicenter trial, a
ow-dose sirolimus regimen yielded worse outcomes owing
o an excess acute rejection rate.30
Thus, it is important to have data that properly assess the
safety and advantage of preventing and even treating de
novo malignancies after transplantation with sirolimus, to
balance the difficult side effect profile.
We acknowledge some limitations in our study: the small
number of patients, its retrospective nature, varying follow-up
intervals, heterogeneity of neoplasms, and tumor behavior,
as well as variable immunosuppression limits our ability to
draw conclusions. Nevertheless, our study provides addi-
tional data in a large cohort of transplant patients. Previous
reports suffer from the same limitations. Therefore, it is
important to have powerful data with larger series (which
are still lacking in the literature). It is of paramount
importance to conduct randomized clinical trials to eluci-
date the best immunosuppressive regimen with the lowest
risk of developing de novo cancer, and with fewer side
effects.
It is strictly important to have evidence-based data to
know if differences among immunosuppressive drugs in
carcinogenic activity are clinically relevant in terms of
survival; if the immunosuppressive therapy should be
adapted to pretransplant malignancy risk; and, lastly, what
is the best approach to manage the immunosuppressive
regimen after a renal recipient develops a de novo malig-
nancy.
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